Stockholders' Equity (Deficit) (Tables)

12 Months Ended

Dec. 31, 2021

Equity [Abstract]

Schedule of Shares Reserved for Future Issuance

The Company has reserved shares of common stock for future issuances as follows:

	December, 31
	2021	2020
Series A redeemable convertible preferred stock outstanding	—	450,692
Series B redeemable convertible preferred stock outstanding	—	675,397
Series C redeemable convertible preferred stock outstanding	—	2,223,888
Series D redeemable convertible preferred stock outstanding	—	9,047,861
Warrants to purchase Series D redeemable convertible preferred stock	—	77,842
Warrants to purchase common stock	77,842	—
Common stock options issued and outstanding	2,175,685	2,466,594
Common stock available for future grants	1,934,095	67,065
Restricted stock units issued and outstanding	394,750	—
Common stock available for ESPP	401,164	—

Schedule of Stock Option Activity

A summary of stock option activity is set forth below (in thousands, except share and per share data):

	Number of Shares Underlying Outstanding Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding, January 1, 2020	2,482,957	$	2.96	5.59	2,257
Options granted	451,689	$	0.61
Options exercised	(282,813)	$	0.73
Options forfeited or cancelled	(185,239)	$	1.28
Outstanding, December 31, 2020	2,466,594	$	0.61	5.21	—
Options granted	1,846,375	$	11.05
Options exercised	(1,975,918)	$	0.61
Options forfeited or cancelled	(161,366)	$	3.28
Outstanding, December 31, 2021	2,175,685	$	9.27	8.68	2,856
Shares exercisable December 31, 2021	1,502,978	$	9.32	8.40	2,066
Vested and expected to vest, December 31, 2021	2,175,685	$	9.27	8.68	2,856

Schedule of Restricted Stock Units

In December 2021 the Company granted 394,750 restricted stock units under 2021 Plan, established by the Company in October 2021.

	Number of Shares Underlying Outstanding Restricted Stock	Weighted Average Grant Date Fair Value
Unvested, January 1, 2021	—	$	—
Granted	394,750	$	5.17
Unvested, December 31, 2021	394,750	$	5.17

Summary of Stock-Based Compensation Expense

Total stock-based compensation expense recognized was as follows (in thousands):

	Years Ended December 31,
	2021		2020
Cost of goods sold	$	274	$	132
Sales and marketing		2,137		311
Research and development		136		10
General and administrative		4,270		405
Total	$	6,817	$	858

The above stock-based compensation expense related to the following equity-based awards (in thousands):

	Years Ended December 31,
	2021		2020
Stock options	$	6,722	$	858
RSU		95		—
Total	$	6,817	$	858

Schedule of Fair Value of Stock Options Estimated Using Weighted-Average Assumptions

The fair value of stock options was estimated using the following weighted-average assumptions:

	Years Ended December 31,
	2021	2020
Expected volatility	72.8% - 78.0%	61.6% - 75.2%
Risk-free interest rate	0.6% - 1.3%	0.3% - 0.7%
Dividend yield	0%	0%
Expected term	5 - 6 years	5 - 6 years